Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study

Harold E. Lebovitz, Alexander Fleming, Alan D. Cherrington, Shashank Joshi, Sandeep N. Athalye, Subramanian Loganathan, Ashwini Vishweswaramurthy, Jayanti Panda, Ashwani Marwah

Expert Opinion on Pharmacotherapy · 2022 · 15 citations · 11 references

Abstract

The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT03430856).

References

11